Polypharmacy is associated with drug–drug interactions, adverse drug events, hospitalization, increased mortality and rising costs. Older cancer patients are potentially vulnerable to polypharmacy because cancer treatment often involves exposure to chemotherapy and other adjunctive or supportive medication.
